Search

Displaying results 5111 - 5120 of 8974 in total
  1. Drug

    SAR445136

    go.drugbank.com/drugs/DB17708
    Investigational

    It consists of autologous CD34+ hematopoietic stem precursor cells (HSPC) modified ex vivo by zinc finger nucleases (ZFN) that target the BCL11A gene erythroid-specific enhancer (ESE) to increase endogenous … [A259063] It was formerly investigated for the treatment of beta-thalassemia, and it is currently being investigated for the treatment of sickle cell disease.[L46148]

  2. Drug

    Trapidil

    go.drugbank.com/drugs/DB09283
    Experimental

    Trapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney

  3. Drug

    Arundic acid

    go.drugbank.com/drugs/DB05343
    Investigational

    Arundic acid has been investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).

  4. Drug

    Amilomotide

    go.drugbank.com/drugs/DB05150
    Investigational

    CAD106 is an immunotherapeutic product in development for the treatment of Alzheimer's disease. … It is designed to induce antibodies against the beta-amyloid-protein that inhibit the formation of plaques in the brain of Alzheimer's disease patients.

  5. Drug

    Toloxatone

    go.drugbank.com/drugs/DB09245
    Experimental

    Toloxatone is an antidepressant agent, the first ever use of which was in France, 1984. It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) .

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substrates
  6. Drug

    Antipain

    go.drugbank.com/drugs/DB15251
    Experimental

    [A214490] The binding of antipain to OPB has been used in molecular dynamic studies to identify other OPB inhibitors with more favourable pharmacodynamic and pharmacokinetic properties for potential development … [A214481] Early studies investigated the potential for antipain to alter DNA damage and chromosomal aberrations in irradiated cells or those treated with chemical mutagens such as _N_-methyl-_N_'-nitro

  7. Drug

    Cimetropium

    go.drugbank.com/drugs/DB09271
    Investigational

    It is also endowed of a direct myolitic action which partially accounts for its antispasmodic activity. It has never been approved for use in the U.S. or Canada.

    Categories: Drugs for Functional Gastrointestinal Disorders
  8. Drug

    Androstenediol

    go.drugbank.com/drugs/DB01524
    ExperimentalIllicit

    Androstenediol, derived from dehydroepiandrosterone by the reduction of the 17-keto group (17-hydroxysteroid dehydrogenases), is converted to testosterone by the oxidation of the 3-beta hydroxyl group … to a 3-keto group (3-hydroxysteroid dehydrogenases).

  9. Drug

    SYN-101

    go.drugbank.com/drugs/DB05958
    Experimental

    SYN-101 is an investigational antibody-drug conjugate developed for the treatment of cancer. … SYN101 is comprised of an immune cell specific antibody linked to an ALK5 inhibitor payload to selectively block TGF-b signalling in immune cells.

  10. Drug

    KB001

    go.drugbank.com/drugs/DB05222
    Investigational

    KB001 is a Humaneered™ PEGylated monoclonal antibody fragment for the treatment of life-threatening Pseudomonas aeruginosa infections, a common problem of cystic fibrosis and mechanically ventilated